Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

Tennessee ,United States ,New York ,Kentucky ,Poland ,Denmark ,California ,United Kingdom ,Brooklyn ,American ,Americans ,Kaiser Permanente ,Mary Beth Lang ,Rachel Shubert ,Paul Holmes ,Richard Gonzalez ,Alex Jung ,Siddharth Singh ,Antonio Ciaccia ,Michael Thompson ,Greg Baker ,Madelaine Feldman ,Coherus Biosciences ,Mark Cuban ,Juliana Reed ,Kevin Ali ,Cora Opsahl ,Keith Athow ,Midwest Business Group On Health ,Bj Health Fund ,Health News ,National Alliance Of Healthcare Purchaser Coalitions ,American College Of Rheumatology ,Biosimilars Forum ,American Gastroenterological Association ,Kroger ,Service Employees International Union ,Arthur Allen ,Williams Barber Morel ,Express Scripts ,Federal Trade Commission ,Blue Shield ,Cost Plus Drugs ,Sue Lee ,National Alliance ,Healthcare Purchaser ,Midwest Business Group ,Marcus Snow ,American College ,New Orleans ,Gastroenterological Association ,Inflation Reduction Act ,Rich Lieblich ,